All patients included in this study were on targeted therapy at the time of COVID-19 vaccination, mostly (50.3%) on tumour necrosis factor inhibitor (TNF-i) (44% of patients with RA and 62.2% of patients with PsA), followed by Janus kinase inhibitor (JAK-i) in 18.2% of patients with RA and interleukin-17 inhibitor (IL-17-i) in 20.2% of patients with PsA. The gene discussed is IL17A; the disease is rheumatoid arthritis.